Abstract：
Monitoring SARS-CoV-2 antibody levels can provide insights into a person\'s immunity to COVID-19 and inform decisions about vaccination and public health measures. Anti-S may be useful as an indicator of an effective immune response. Thus, we conducted this study that aimed to determine the immune response of anti-S antibodies against SARS-CoV-2 for all the vaccine types over time among adult recipients in Malaysia and to determine the associated factors. This study was a cohort that recruited 2513 respondents aged 18 years and above from June to December 2021. Each participant was followed-up for 1-year period from the initial vaccine dose (baseline). We found that the anti-S antibody generally increased for all vaccine types and peaked at two weeks after the second dose vaccination, with Pfizer recipients having the highest median of 100 (100.00-100.00). During the third-month follow-up, the seropositivity of anti-S antibody and the median level decreased for all vaccines. We found that type of vaccines, comorbid status, infection, and booster status were significantly associated with the anti-S antibody level after one year.
摘要：
监测SARS-CoV-2抗体水平可以深入了解一个人对COVID-19的免疫力，并为疫苗接种和公共卫生措施提供信息。抗S可用作有效免疫应答的指示物。因此，我们进行了这项研究,目的是确定马来西亚成年受者对所有类型SARS-CoV-2的抗S抗体随时间变化的免疫应答,并确定相关因素.这项研究是一个队列，从2021年6月至2021年12月招募了2513名18岁及以上的受访者。每个参与者从初始疫苗剂量（基线）开始随访1年。我们发现，所有疫苗类型的抗S抗体通常都会增加，并在第二剂疫苗接种后2周达到峰值，辉瑞公司的受助人中位数最高，为100人(100-100人)。在第三个月的随访中，所有疫苗的抗S抗体血清阳性和中位水平均下降.我们发现这种疫苗，合并症状态，感染,和加强状态与1年后的抗S抗体水平显着相关。
